(firstQuint)Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer.

 Phase I Objectives - To determine the Maximum Tolerated Dose (MTD) of the combination of (DOXIL) and Abraxane in patients with Metastatic Breast Cancer (MBC).

 - Determine the dose-limiting toxicity (DLT) of DOXIL and Abraxane.

 Phase II Objectives Primary Objective - To determine the response rate of DOXIL and Abraxane in patients with MBC.

 Secondary Objectives - To determine the time to disease progression in patients with MBC receiving DOXIL and Abraxane.

 - To assess the tolerability of this regimen in women with MBC and assess toxicity profile.

 Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer@highlight

Dose Finding and Efficacy Evaluation of DOXIL (Doxorubicin HCL Liposome Injection) in Combination with Abraxane (Abraxane) in Patients with Metastatic Breast Cancer (MBC) [Phase I and II]